Non-Alcoholic Fatty Liver Disease Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Guangdong Raynovent, Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuti

Non-Alcoholic Fatty Liver Disease Pipeline constitutes 90+ key companies continuously working towards developing 100+ Non-Alcoholic Fatty Liver Disease treatment therapies, analyzes DelveInsight.

Non-Alcoholic Fatty Liver Disease Overview:

Non-alcoholic fatty liver disease (NAFLD) is an umbrella term that includes a range of liver conditions marked by the presence of hepatic steatosis (fat accumulation in the liver), as seen through imaging or histological examination-typically macrovesicular steatosis. It is diagnosed when there are no other identifiable causes of fat buildup in the liver, such as heavy alcohol intake, long-term use of certain medications, or inherited liver disorders. In Western countries, NAFLD affects approximately 20-30% of the population.

Risk factors commonly linked to NAFLD include obesity, type 2 diabetes, abnormal lipid levels, insulin resistance, and metabolic syndrome. Additionally, research has shown a potential link between exposure to inorganic arsenic and the onset of NAFLD, as indicated by increased levels of alanine aminotransferase (ALT). Because of its strong connection with metabolic syndrome, NAFLD is also associated with cardiovascular risk factors, which contribute to patient mortality-alongside progression to end-stage liver disease and liver cancer (hepatocellular carcinoma).

Download our report @ https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Non-Alcoholic Fatty Liver Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-Alcoholic Fatty Liver Disease Therapeutics Market.

Key Takeaways from the Non-Alcoholic Fatty Liver Disease Pipeline Report

DelveInsight's Non-Alcoholic Fatty Liver Disease pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for Non-Alcoholic Fatty Liver Disease treatment.
​In March 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Madrigal Pharmaceuticals' RezdiffraTM (resmetirom) for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. This approval marks a significant milestone, as Rezdiffra is the first medication approved by the FDA specifically for NASH, also known as metabolic dysfunction-associated steatohepatitis (MASH). ​
Key Non-Alcoholic Fatty Liver Disease companies such as Guangdong Raynovent, Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca, and others are evaluating new drugs for Non-Alcoholic Fatty Liver Disease to improve the treatment landscape.
Promising Non-Alcoholic Fatty Liver Disease pipeline therapies in various stages of development include Lanifibranor, ZED 1227, TVB-2640, ALS-L1023, AZD9550, and others.

Non-Alcoholic Fatty Liver Disease Pipeline Analysis
The Non-Alcoholic Fatty Liver Disease pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Non-Alcoholic Fatty Liver Disease Market.

Categorizes Non-Alcoholic Fatty Liver Disease therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Non-Alcoholic Fatty Liver Disease drugs under development based on:

Stage of development

Non-Alcoholic Fatty Liver Disease Route of administration

Target receptor

Monotherapy vs. combination therapy

Non-Alcoholic Fatty Liver Disease Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Non-Alcoholic Fatty Liver Disease Licensing agreements

Funding and investment activities supporting future Non-Alcoholic Fatty Liver Disease market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-Alcoholic Fatty Liver Disease Emerging Drugs

Lanifibranor: Inventiva Pharma
ZED 1227: Dr. Falk Pharma GmbH
TVB-2640: Sagimet Biosciences
AngioLab
AZD9550: AstraZeneca

Non-Alcoholic Fatty Liver Disease Companies

Over 90 prominent companies are currently engaged in developing treatments for Non-Alcoholic Fatty Liver Disease (NAFLD). Among these, Inventiva Pharma stands out with a drug candidate that has reached the most advanced stage of development-Phase III clinical trials.

DelveInsight's report covers around 100+ products under different phases of Non-Alcoholic Fatty Liver Disease clinical trials like

Non-Alcoholic Fatty Liver Disease Late stage Therapies (Phase III)
Non-Alcoholic Fatty Liver Disease Mid-stage Therapies (Phase II)
Non-Alcoholic Fatty Liver Disease Early-stage Therapies (Phase I)
Non-Alcoholic Fatty Liver Disease Pre-clinical and Non-Alcoholic Fatty Liver Disease Discovery stage Therapies
Non-Alcoholic Fatty Liver Disease Discontinued & Inactive Therapies

Non-Alcoholic Fatty Liver Disease pipeline report provides the Non-Alcoholic Fatty Liver Disease therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Non-Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Non-Alcoholic Fatty Liver Disease Therapies and Key Non-Alcoholic Fatty Liver Disease Companies: Non-Alcoholic Fatty Liver Disease Clinical Trials and recent advancements https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-Alcoholic Fatty Liver Disease Pipeline Therapeutic Assessment
• Non-Alcoholic Fatty Liver Disease Assessment by Product Type
• Non-Alcoholic Fatty Liver Disease By Stage
• Non-Alcoholic Fatty Liver Disease Assessment by Route of Administration
• Non-Alcoholic Fatty Liver Disease Assessment by Molecule Type

Download Non-Alcoholic Fatty Liver Disease Sample report to know in detail about the Non-Alcoholic Fatty Liver Disease treatment market @ Non-Alcoholic Fatty Liver Disease Therapeutic Assessment https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Non-Alcoholic Fatty Liver Disease Current Treatment Patterns
4. Non-Alcoholic Fatty Liver Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-Alcoholic Fatty Liver Disease Late-Stage Products (Phase-III)
7. Non-Alcoholic Fatty Liver Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Alcoholic Fatty Liver Disease Discontinued Products
13. Non-Alcoholic Fatty Liver Disease Product Profiles
14. Non-Alcoholic Fatty Liver Disease Key Companies
15. Non-Alcoholic Fatty Liver Disease Key Products
16. Dormant and Discontinued Products
17. Non-Alcoholic Fatty Liver Disease Unmet Needs
18. Non-Alcoholic Fatty Liver Disease Future Perspectives
19. Non-Alcoholic Fatty Liver Disease Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Non-Alcoholic Fatty Liver Disease Pipeline Reports Offerings: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.